LKFT

Mechelen, Belgium; 01 September 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that between August 24, 2026 and August 28, 2026 it has repurchased 127,796 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) 24/08/2026 XAMS 21,820 24.56 535,857.74 24.36 24.64 24/08/2026 TQEX 450 24.55 11,045.43 24.54 24.60 24/08/2026 CEUX 328 24.58 8,062.37 24.54 24.64 24/08/2026 AQEU 1,333 24.61 32,811.40 24.58 24.66 25/08/2026 XAMS 21,058 25.29 532,464.16 24.94 25.52 25/08/2026 TQEX 698 25.25 17,623.66 25.00 25.36 25/08/2026 CEUX 600 25.28 15,165.48 25.24 25.34 25/08/2026 AQEU 313 25.29 7,914.33 25.26 25.34 26/08/2026 XAMS 22,968 25.45 584,632.07 25.08 25.64 26/08/2026 TQEX 599 25.45 15,241.91 25.30 25.64 26/08/2026 CEUX 1,703 25.47 43,377.62 25.24 25.66 26/08/2026 AQEU 539 25.50 13,744.72 25.32 25.60 27/08/2026 XAMS 21,382 25.27 540,406.53 25.06 25.36 27/08/2026 TQEX 904 25.27 22,843.72 25.20 25.32 27/08/2026 CEUX 2,342 25.24 59,114.89 25.12 25.36 27/08/2026 AQEU 440 25.23 11,100.50 25.12 25.34 28/08/2026 XAMS 25,694 25.29 649,927.16 25.00 25.50 28/08/2026 TQEX 1,110 25.40 28,194.11 25.36 25.46 28/08/2026 CEUX 3,363 25.38 85,342.18 25.08 25.46 28/08/2026 AQEU 152 25.26 3,840.17 25.14 25.46 Total   127,796 25.19 3,218,710.15 24.36 25.66 As of market close on 28 August 2026, Lakefront holds 1,161,324 of its own ordinary shares. About Lakefront Biotherapeutics Lakefront Biotherapeutics is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need.

Mechelen, Belgium; 25 August 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that between August 17, 2026 and August 21, 2026, it has repurchased 117,471 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) 17/08/2026 XAMS 16,158 23.97 387,350.89 23.84 24.20 17/08/2026 CEUX 2,196 23.98 52,664.03 23.90 24.18 17/08/2026 TQEX 611 24.07 14,706.59 23.94 24.20 17/08/2026 AQEU 1,008 24.04 24,227.68 23.94 24.04 18/08/2026 XAMS 23,094 23.82 550,184.53 23.66 24.00 18/08/2026 CEUX 2,137 23.79 50,833.25 23.66 23.94 18/08/2026 TQEX 737 23.87 17,593.07 23.70 23.90 18/08/2026 AQEU 562 23.82 13,389.14 23.72 23.86 19/08/2026 XAMS 16,677 24.83 414,059.89 24.16 25.70 19/08/2026 CEUX 1,953 24.67 48,186.37 24.36 25.52 19/08/2026 TQEX 1,329 24.52 32,583.23 24.36 24.66 19/08/2026 AQEU 224 24.59 5,507.89 24.40 24.60 20/08/2026 XAMS 24,144 24.92 601,772.30 24.36 25.68 20/08/2026 CEUX 2,709 25.29 68,501.13 25.10 25.70 20/08/2026 TQEX 962 24.89 23,940.04 24.44 25.14 20/08/2026 AQEU 1,209 25.25 30,521.69 25.10 25.42 21/08/2026 XAMS 14,694 24.38 358,210.33 24.14 25.00 21/08/2026 CEUX 5,347 24.31 130,010.17 24.18 24.84 21/08/2026 TQEX 381 24.57 9,360.83 24.24 24.90 21/08/2026 AQEU 1,339 24.22 32,432.05 24.22 24.24 Total   117,471 24.40 2,866,035.10 23.66 25.70 As of market close on 21 August 2026, Lakefront holds 1,033,528 of its own ordinary shares. About Lakefront Biotherapeutics Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need.

Mechelen, Belgium; 24 August 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to gamgertamig for the treatment of pemphigus. Gamgertamig was previously granted both Fast Track and Orphan Drug Designation by the U.S. FDA for the treatment of autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP).

Mechelen, Belgium; August 24, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) received a transparency notification from Bank of America.

Mechelen, Belgium; 18 August 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that between August 10, 2026 and August 14, 2026, it has repurchased 107,871 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) 10/08/2026 XAMS 18,754 23.53 441,208.48 23.24 23.64 10/08/2026 AQEU 1 23.54 23.54 23.54 23.54 10/08/2026 CEUX 2,234 23.42 52,317.60 23.28 23.62 10/08/2026 TQEX 551 23.46 12,927.51 23.32 23.64 11/08/2026 XAMS 14,810 24.07 356,417.46 22.88 24.52 11/08/2026 CEUX 1,014 24.12 24,453.02 23.76 24.48 11/08/2026 TQEX 496 24.34 12,070.26 24.04 24.42 12/08/2026 XAMS 19,360 24.64 476,972.32 24.40 24.98 12/08/2026 AQEU 310 24.59 7,622.28 24.46 24.62 12/08/2026 CEUX 764 24.53 18,744.36 24.44 24.64 12/08/2026 TQEX 141 24.48 3,451.82 24.46 24.54 13/08/2026 XAMS 18,473 24.40 450,696.86 24.20 24.50 13/08/2026 AQEU 13 24.40 317.20 24.40 24.40 13/08/2026 CEUX 3,090 24.38 75,331.11 24.18 24.50 13/08/2026 TQEX 1,381 24.41 33,706.07 24.34 24.50 14/08/2026 XAMS 23,317 24.09 561,603.94 23.76 24.42 14/08/2026 AQEU 163 24.09 3,927.39 23.94 24.16 14/08/2026 CEUX 2,337 24.06 56,217.70 23.90 24.24 14/08/2026 TQEX 662 24.16 15,993.66 23.90 24.36 Total   107,871 24.14 2,604,002.56 22.88 24.98 As of market close on 14 August 2026, Lakefront holds 916,057 of its own ordinary shares. About Lakefront Biotherapeutics Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need.

Mechelen, Belgium; 12 August 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that between August 3, 2026 and August 7, 2026, it has repurchased 103,970 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) 03/08/2026 XAMS 16,017 23.56 377,368.53 23.10 23.86 03/08/2026 CEUX 2,367 23.61 55,891.02 23.26 23.84 03/08/2026 AQEU 876 23.70 20,761.46 23.70 23.72 03/08/2026 TQEX 704 23.75 16,720.35 23.62 23.86 04/08/2026 XAMS 17,257 23.31 402,305.54 23.18 23.48 04/08/2026 CEUX 2,485 23.26 57,801.85 23.18 23.40 04/08/2026 AQEU 55 23.24 1,278.20 23.24 23.24 04/08/2026 TQEX 722 23.33 16,842.60 23.20 23.40 05/08/2026 XAMS 17,763 23.17 411,650.42 22.96 23.32 05/08/2026 CEUX 2,382 23.12 55,068.98 22.90 23.28 05/08/2026 AQEU 604 23.18 14,003.62 23.08 23.24 05/08/2026 TQEX 170 23.20 3,944.00 23.20 23.20 06/08/2026 XAMS 17,857 22.64 404,205.69 22.32 22.88 06/08/2026 CEUX 1,987 22.49 44,681.07 22.36 22.70 06/08/2026 AQEU 743 22.65 16,831.55 22.42 22.72 06/08/2026 TQEX 533 22.57 12,030.61 22.44 22.76 07/08/2026 XAMS 17,738 23.24 412,179.68 22.88 23.44 07/08/2026 CEUX 2,842 23.26 66,112.88 23.12 23.40 07/08/2026 AQEU 199 23.29 4,634.37 23.26 23.38 07/08/2026 TQEX 669 23.30 15,588.97 23.18 23.46 Total   103,970 23.18 2,409,901.40 22.32 23.86 As of market close on 07 August 2026, Lakefront holds 808,186 of its own ordinary shares. About Lakefront Biotherapeutics Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need.

Mechelen, Belgium; July 28, 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that between July 20, 2026 and July 24, 2026, it has repurchased 95,670 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) 20/07/2026 XAMS 17,936 26.05 467,150.29 25.62 26.40 20/07/2026 CEUX 3,372 25.79 86,979.73 25.70 26.14 20/07/2026 AQEU 101 25.72 2,597.72 25.72 25.72 20/07/2026 TQEX 74 26.22 1,940.28 26.22 26.22 21/07/2026 XAMS 14,022 25.59 358,820.18 25.34 25.80 21/07/2026 CEUX 1,506 25.57 38,513.84 25.52 25.66 21/07/2026 AQEU 227 25.53 5,795.01 25.52 25.70 21/07/2026 TQEX 506 25.56 12,931.79 25.52 25.58 22/07/2026 XAMS 15,385 25.61 394,028.31 25.48 25.72 22/07/2026 CEUX 1,245 25.63 31,907.36 25.62 25.68 22/07/2026 AQEU 490 25.62 12,553.80 25.62 25.62 22/07/2026 TQEX 185 25.68 4,750.13 25.62 25.68 23/07/2026 XAMS 17,120 25.13 430,292.37 24.70 25.62 23/07/2026 CEUX 2,945 24.81 73,071.34 24.74 25.12 23/07/2026 AQEU 61 24.78 1,511.58 24.78 24.78 23/07/2026 TQEX 61 24.78 1,511.58 24.78 24.78 24/07/2026 XAMS 17,407 24.81 431,940.78 24.56 25.00 24/07/2026 CEUX 1,729 24.77 42,830.62 24.60 24.98 24/07/2026 AQEU 1,159 24.91 28,875.91 24.62 24.96 24/07/2026 TQEX 139 24.75 3,439.68 24.62 24.92 Total   95,670 25.41 2,431,442.30 24.56 26.40 As of market close on July 24, 2026, Lakefront holds 606,719 of its own ordinary shares. About Lakefront Biotherapeutics Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need.

Mechelen, Belgium; July 21, 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that between July 13, 2026 and July 17, 2026 it has repurchased 98,648 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) 13/07/2026 XAMS 20,583 26.38 543,006.30 26.12 26.56 13/07/2026 CEUX 1,842 26.39 48,613.33 26.30 26.54 13/07/2026 AQEU 238 26.41 6,286.13 26.34 26.54 13/07/2026 TQEX 532 26.41 14,049.69 26.34 26.46 14/07/2026 XAMS 19,825 26.01 515,672.04 25.74 26.34 14/07/2026 CEUX 2,289 25.99 59,486.07 25.84 26.20 14/07/2026 AQEU 170 25.86 4,396.20 25.86 25.86 14/07/2026 TQEX 987 26.08 25,736.81 26.06 26.18 15/07/2026 XAMS 15,770 25.75 406,156.35 25.62 25.96 15/07/2026 CEUX 422 25.73 10,857.47 25.62 25.78 15/07/2026 AQEU 476 25.72 12,244.15 25.62 25.76 15/07/2026 TQEX 906 25.79 23,368.73 25.62 25.80 16/07/2026 XAMS 16,485 25.93 427,428.03 25.76 26.10 16/07/2026 CEUX 1,137 25.93 29,483.89 25.88 26.00 16/07/2026 AQEU 68 25.92 1,762.56 25.92 25.92 16/07/2026 TQEX 528 25.94 13,695.21 25.92 25.94 17/07/2026 XAMS 14,972 25.77 385,768.55 25.60 26.04 17/07/2026 CEUX 1,368 25.83 35,337.22 25.70 26.02 17/07/2026 TQEX 50 25.70 1,285.00 25.70 25.70 Total   98,648 26.00 2,564,633.73 25.60 26.56 As of market close on July 17, 2026, Lakefront holds 511,049 of its own ordinary shares. About Lakefront Biotherapeutics Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need.

Mechelen, Belgium; 14 July 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that it has repurchased 108,645 Lakefront shares between 06 July 2026 and 10 July 2026, as follows: Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€) 06/07/2026 XAMS 20,236 26.54 536,964.28 26.20 26.90 06/07/2026 CEUX 2,499 26.69 66,710.06 26.32 26.90 06/07/2026 TQEX 355 26.72 9,486.20 26.52 26.90 06/07/2026 AQEU 319 26.58 8,477.65 26.52 26.88 07/07/2026 XAMS 16,553 26.65 441,104.34 26.40 26.86 07/07/2026 CEUX 1,578 26.55 41,894.01 26.44 26.76 07/07/2026 TQEX 821 26.64 21,872.92 26.60 26.70 07/07/2026 AQEU 49 26.60 1,303.40 26.60 26.60 08/07/2026 XAMS 17,502 26.84 469,793.93 26.66 27.00 08/07/2026 CEUX 4,339 26.89 116,674.84 26.74 26.96 08/07/2026 TQEX 1,157 26.87 31,086.62 26.76 26.94 08/07/2026 AQEU 416 26.86 11,172.18 26.80 26.94 09/07/2026 XAMS 16,919 26.77 452,892.87 26.56 26.90 09/07/2026 CEUX 2,717 26.79 72,781.09 26.70 26.96 09/07/2026 TQEX 23 26.76 615.48 26.76 26.76 09/07/2026 AQEU 400 26.77 10,707.04 26.76 26.78 10/07/2026 XAMS 19,764 26.52 524,208.48 26.14 26.90 10/07/2026 CEUX 2,009 26.66 53,568.98 26.26 26.92 10/07/2026 TQEX 692 26.65 18,443.74 26.24 26.78 10/07/2026 AQEU 297 26.82 7,964.53 26.26 26.92 Total   108,645 26.67 2,897,722.65 26.14 27.00 As of market close on 10 July 2026, Lakefront holds 412,401 of its own ordinary shares. About Lakefront Biotherapeutics Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need.

Mechelen, Belgium; July 13, 2026, 22:01 CET; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that following his appointment as Executive Vice President, Global Head of Research & Development Pharma at Sanofi SA, Dr. Paulo Fontoura has tendered his resignation from the Board of Directors.